XCUR
Exicure, Inc. [XCUR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XCUR Stock Summary
Top 10 Correlated ETFs
XCUR
Top 10 Correlated Stocks
XCUR
In the News
XCUR Financial details
Company Rating
Neutral
Market Cap
5.02M
Income
3.07M
Revenue
23.79M
Book val./share
1.15
Cash/share
0.28
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
1.47
Forward P/E
-
PEG
-0.14
P/S
0.2
P/B
0.54
P/C
2.11
P/FCF
-0.24
Quick Ratio
1.63
Current Ratio
2.56
Debt / Equity
0.72
LT Debt / Equity
0.66
-
-
EPS (TTM)
1.28
EPS next Y
-
EPS next Q
-
EPS this Y
-97.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-49.06%
Revenue last 5Y
200.32%
Revenue Q/Q
-
EPS Q/Q
-2.86%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
8.23%
Inst Trans
0.01%
ROA
20%
ROE
40%
ROC
0.2%
Gross Margin
70%
Oper. Margin
12%
Profit Margin
14%
Payout
1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.365-1.5
52W High
-
52W Low
-
RSI
46
Rel Volume
0.09
Avg Volume
225.58K
Volume
20.02K
Perf Week
0.63%
Perf Month
-10.38%
Perf Quarter
-7.66%
Perf Half Y
-15.62%
-
-
-
-
Beta
1.225
-
-
Volatility
0.02%, 0.03%
Prev Close
2.19%
Price
0.5915
Change
-1.42%
XCUR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.09 | 0.67 | 5.72 | -0.16 | 6.24 | |
| Net income per share | -16.32 | -13.68 | -8.49 | -21.7 | -0.56 | |
| Operating cash flow per share | -14.19 | 0.69 | -13.51 | -11.79 | -7.72 | |
| Free cash flow per share | -14.26 | 0.12 | -14.6 | -12.12 | -7.72 | |
| Cash per share | 19.13 | 57.63 | 28.24 | 13.25 | 1.86 | |
| Book value per share | 15.26 | 42 | 21.16 | 3.8 | 3.23 | |
| Tangible book value per share | 15.26 | 42 | 21.16 | 3.8 | 3.23 | |
| Share holders equity per share | 15.26 | 42 | 21.16 | 3.8 | 3.23 | |
| Interest debt per share | 4.08 | 3.17 | 8.72 | 5.56 | 1.71 | |
| Market cap | 145.81M | 164.94M | 154.35M | 17.9M | 5.31M | |
| Enterprise value | 124.47M | 121.8M | 145.86M | -2.01M | 4.04M | |
| P/E ratio | -6.51 | -6.27 | -6.26 | -0.28 | -2.06 | |
| Price to sales ratio | 1.24K | 127.27 | 9.29 | -37.06 | 0.18 | |
| POCF ratio | -7.48 | 125.24 | -3.93 | -0.51 | -0.15 | |
| PFCF ratio | -7.45 | 701.88 | -3.64 | -0.5 | -0.15 | |
| P/B Ratio | 6.96 | 2.04 | 2.51 | 1.59 | 0.36 | |
| PTB ratio | 6.96 | 2.04 | 2.51 | 1.59 | 0.36 | |
| EV to sales | 1.05K | 93.98 | 8.78 | 4.16 | 0.14 | |
| Enterprise value over EBITDA | -5.73 | -4.81 | -6.43 | 0.03 | -7.28 | |
| EV to operating cash flow | -6.39 | 92.48 | -3.71 | 0.06 | -0.11 | |
| EV to free cash flow | -6.36 | 518.29 | -3.44 | 0.06 | -0.11 | |
| Earnings yield | -0.15 | -0.16 | -0.16 | -3.58 | -0.49 | |
| Free cash flow yield | -0.13 | 0 | -0.27 | -2 | -6.71 | |
| Debt to equity | 0.24 | 0.07 | 0.4 | 1.31 | 0.49 | |
| Debt to assets | 0.17 | 0.05 | 0.25 | 0.23 | 0.31 | |
| Net debt to EBITDA | 0.98 | 1.7 | 0.37 | 0.33 | 2.29 | |
| Current ratio | 13.54 | 3.63 | 6.29 | 1.28 | 6.13 | |
| Interest coverage | -32.47 | -33.86 | -44.39 | -36.99 | -3.08 | |
| Income quality | 0.87 | -0.05 | 1.59 | 0.54 | 13.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 66.25 | 6.61 | 0.6 | -27.1 | 0.38 | |
| Research and developement to revenue | 119.65 | 14.92 | 1.93 | -101.41 | 0.69 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | -0.82 | 0.08 | 0.03 | 0 | |
| Capex to revenue | -0.8 | -0.83 | -0.19 | 2 | 0 | |
| Capex to depreciation | -0.26 | -1.49 | -2.19 | -0.54 | -0.01 | |
| Stock based compensation to revenue | 15.33 | 1.42 | 0.13 | -6.08 | 0.05 | |
| Graham number | 74.87 | 113.71 | 63.56 | 43.09 | 6.37 | |
| ROIC | -0.86 | -0.32 | -0.28 | -1.9 | -0.07 | |
| Return on tangible assets | -0.78 | -0.23 | -0.25 | -0.99 | -0.11 | |
| Graham Net | 13.69 | 39.69 | 15.37 | -4.91 | 0.04 | |
| Working capital | 25.62M | 81.69M | 72.59M | 9.6M | 8.41M | |
| Tangible asset value | 20.95M | 80.75M | 61.51M | 11.23M | 14.92M | |
| Net current asset value | 19.86M | 78.26M | 47.38M | -9.97M | 1.65M | |
| Invested capital | 0.24 | 0.07 | 0.4 | 1.31 | 0.49 | |
| Average receivables | 16.5K | 19K | 23K | 5.5K | 0 | |
| Average payables | 774.5K | 1.16M | 1.84M | 2.64M | 1.89M | |
| Average inventory | 323K | 323K | 1.52M | 1.52M | 0 | |
| Days sales outstanding | 9.28 | 9.86 | 0.24 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 700.25 | 70.99 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 39.33 | 37.03 | 1.51K | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0.52 | 5.14 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.07 | -0.33 | -0.4 | -5.71 | -0.17 | |
| Capex per share | -0.07 | -0.56 | -1.09 | -0.33 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.55 | 0.41 | 4.38 | 0 | 0 | |
| Net income per share | -1.66 | -1.04 | 3.7 | -0.7 | -0.68 | |
| Operating cash flow per share | -2.02 | -1.32 | -1.47 | -0.53 | -0.57 | |
| Free cash flow per share | -2.02 | -1.32 | -1.47 | -0.53 | -0.57 | |
| Cash per share | 4.93 | 3.15 | 1.73 | 1.58 | 0.28 | |
| Book value per share | 0.26 | -0.75 | 3 | 2.32 | 1.15 | |
| Tangible book value per share | 0.26 | -0.75 | 3 | 2.32 | 1.15 | |
| Share holders equity per share | 0.26 | -0.75 | 3 | 2.32 | 1.15 | |
| Interest debt per share | 1.69 | 1.5 | 1.47 | 1.14 | 0.83 | |
| Market cap | 9.73M | 7.79M | 5.71M | 5.48M | 11.05M | |
| Enterprise value | -3.87M | -401.55K | 4.44M | 2.67M | 15.71M | |
| P/E ratio | -0.33 | -0.38 | 0.08 | -0.31 | -0.48 | |
| Price to sales ratio | 3.94 | 3.87 | 0.26 | 0 | 0 | |
| POCF ratio | -1.07 | -1.19 | -0.78 | -1.65 | -2.3 | |
| PFCF ratio | -1.07 | -1.19 | -0.78 | -1.65 | -2.3 | |
| P/B Ratio | 8.37 | -2.1 | 0.38 | 0.37 | 1.14 | |
| PTB ratio | 8.37 | -2.1 | 0.38 | 0.37 | 1.14 | |
| EV to sales | -1.57 | -0.2 | 0.2 | 0 | 0 | |
| Enterprise value over EBITDA | 0.55 | 0.08 | 0.23 | -0.67 | -2.93 | |
| EV to operating cash flow | 0.43 | 0.06 | -0.61 | -0.81 | -3.27 | |
| EV to free cash flow | 0.43 | 0.06 | -0.61 | -0.81 | -3.27 | |
| Earnings yield | -0.77 | -0.66 | 3.22 | -0.8 | -0.52 | |
| Free cash flow yield | -0.93 | -0.84 | -1.27 | -0.61 | -0.44 | |
| Debt to equity | 6.53 | -2.01 | 0.49 | 0.49 | 0.72 | |
| Debt to assets | 0.21 | 0.26 | 0.31 | 0.3 | 0.4 | |
| Net debt to EBITDA | 1.94 | 1.73 | -0.07 | 0.7 | -0.87 | |
| Current ratio | 1.26 | 0.67 | 6.13 | 4.13 | 2.56 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.22 | 1.27 | -0.4 | 0.75 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.3 | 1.2 | 0.1 | 0 | 0 | |
| Research and developement to revenue | 2.73 | 2.38 | 0.05 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.01 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.21 | 0.14 | 0.01 | 0 | 0 | |
| Graham number | 3.1 | 4.18 | 15.83 | 6.05 | 4.21 | |
| ROIC | -0.46 | -0.46 | 0.62 | -0.16 | -0.23 | |
| Return on tangible assets | -0.2 | -0.18 | 0.79 | -0.18 | -0.33 | |
| Graham Net | -3.02 | -3.42 | 0.03 | 0.1 | -0.65 | |
| Working capital | 5.07M | -8.51M | 8.41M | 8.55M | 2.23M | |
| Tangible asset value | 1.16M | -3.7M | 14.92M | 14.62M | 9.71M | |
| Net current asset value | -11.07M | -15.45M | 1.65M | 1.95M | -4.19M | |
| Invested capital | 6.53 | -2.01 | 0.49 | 0.49 | 0.72 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.76M | 1.26M | 640.5K | 406.5K | 397.5K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 309.65 | 178.45 | 70.94 | 94.39 | 74.93 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.29 | 0.5 | 1.27 | 0.95 | 1.2 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -6.42 | 1.39 | 1.23 | -0.3 | -0.59 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
XCUR Frequently Asked Questions
What is Exicure, Inc. stock symbol ?
Exicure, Inc. is a US stock , located in Chicago of Il and trading under the symbol XCUR
What is Exicure, Inc. stock quote today ?
Exicure, Inc. stock price is $0.5915 today.
Is Exicure, Inc. stock public?
Yes, Exicure, Inc. is a publicly traded company.
Company Profile
- Volume Average 225.58K
- Market Capitalization 5.02M
- Employee 7
- CEO Mr. Paul Kang
- Headquarters Chicago,IL,US
- IPO Date 2018-05-22
-
Website
https://www.exicuretx.com 
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
